Gilead Sciences, Inc [GILD] stock is trading at $120.47, up 0.89%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The GILD shares have gain 5.20% over the last week, with a monthly amount glided 9.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Gilead Sciences, Inc [NASDAQ: GILD] stock has seen the most recent analyst activity on August 08, 2025, when Truist upgraded its rating to a Buy but kept the price target unchanged to $127 for it. Previously, Needham upgraded its rating to Buy on July 25, 2025, and kept the price target unchanged to $133. Oppenheimer reiterated its Outperform rating and increased its price target to $132 on March 04, 2025. Deutsche Bank upgraded its rating to a Buy but $120 remained the price target by the analyst firm on February 18, 2025. DZ Bank upgraded its rating to Buy for this stock on February 13, 2025, but kept the price target unchanged to $108. In a note dated January 10, 2025, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $87 to $113.
Gilead Sciences, Inc [GILD] stock has fluctuated between $72.43 and $121.38 over the past year. Currently, Wall Street analysts expect the stock to reach $126.14 within the next 12 months. Gilead Sciences, Inc [NASDAQ: GILD] shares were valued at $120.47 at the most recent close of the market. An investor can expect a potential return of 4.71% based on the average GILD price forecast.
Analyzing the GILD fundamentals
Gilead Sciences, Inc [NASDAQ:GILD] reported sales of 28.80B for the trailing twelve months, which represents a growth of 1.64%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.28%, Pretax Profit Margin comes in at 0.25%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.33 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 118.89 points at the first support level, and at 117.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 121.33, and for the 2nd resistance point, it is at 122.19.
Ratios To Look Out For
For context, Gilead Sciences, Inc’s Current Ratio is 1.32. In addition, the Quick Ratio stands at 1.15 and the Cash Ratio stands at 0.46. Considering the valuation of this stock, the price to sales ratio is 5.19, the price to book ratio is 7.61 and price to earnings (TTM) ratio is 23.96.
Transactions by insiders
Recent insider trading involved O’Day Daniel Patrick, Chairman & CEO, that happened on Jul 28 ’25 when 10000.0 shares were sold. Officer, DANIEL ODAY completed a deal on Jul 28 ’25 to buy 10000.0 shares. Meanwhile, Chief Commercial Officer Mercier Johanna sold 3000.0 shares on Jul 15 ’25.
